RINATABART SESUTECAN
UNII C56LJ7JC3W

Substance Identification & Data

This profile provides standardized clinical and technical data for Rinatabart Sesutecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) C56LJ7JC3W.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2853518-95-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

C56LJ7JC3W

CAS Registry Number

2853518-95-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RINATABART SESUTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C192818

National Cancer Institute reference terminology for clinical and research data.

INN ID

13030

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-269

Identifier assigned by the United States Adopted Names Council.

Substance Type

Rinatabart Sesutecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Rinatabart Sesutecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Rinatabart Sesutecan

Common Names & Synonyms

Immunoglobulin G1 [240-alanine,241-alanine], anti-(human folate receptor α) (human monoclonal PRO1184 γ1-chain, complex with human monoclonal PRO1184 κ-chain, dimer, 214′′,214′′′,226,226′,232,232′,235,235′-octakis(thioether) with N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide

RINATABART SESUTECAN [USAN]

Rina-S

Rinatabart sesutecan [WHO-DD]

immunoglobulin G1-kappa, anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], Homo sapiens monoclonal antibody, conjugated on an average of 8 cysteinyl residues to sesutecan, comprising a linker and a camptothecin derivative (exatecan); H-gamma1 heavy chain Homo sapiens (1-453) [VH (Homo sapiens IGHV3-30*03 (96.9%) -(IGHD) -IGHJ4*01 (92.9%) L123>Q (118), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v14 CH2 A1.3, A1.2 (CH1 K120 (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>A (241) (237-346), CH3 D12 (362), L14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (93.7%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of an average of 8 L-cysteinyl residues among 226, 232, 235, 214', 226'', 232'', 235'' and 214''' with radical group 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-pentahydroxy-52-{[(2S)-1-{[(2S)-5-carbamoylamino-1-oxo-1-{3-[({[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro1H,12Hbenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}oxy)methyl]anilino}pentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamoyl}-7-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]-46,54-dioxo10,13,16,19,22,25,28,31,34,37,40,43-dodecaoxa-7,47,53-triazanonapentacontan-59-yl]-2,5-dioxopyrrolidin-3-yl (sesutecan)